1. Home
  2. CNA vs ABVX Comparison

CNA vs ABVX Comparison

Compare CNA & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNA Financial Corporation

CNA

CNA Financial Corporation

HOLD

Current Price

$45.58

Market Cap

13.9B

Sector

Finance

ML Signal

HOLD

Logo Abivax SA American

ABVX

Abivax SA American

HOLD

Current Price

$95.18

Market Cap

11.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNA
ABVX
Founded
1853
2013
Country
United States
France
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
13.9B
11.9B
IPO Year
1994
2022

Fundamental Metrics

Financial Performance
Metric
CNA
ABVX
Price
$45.58
$95.18
Analyst Decision
Buy
Analyst Count
0
13
Target Price
N/A
★ $131.31
AVG Volume (30 Days)
529.3K
★ 1.3M
Earning Date
05-04-2026
03-23-2026
Dividend Yield
★ 8.20%
N/A
EPS Growth
★ 33.24
N/A
EPS
★ 1.95
N/A
Revenue
★ $14,989,000,000.00
N/A
Revenue This Year
N/A
$52.14
Revenue Next Year
N/A
$4,132.27
P/E Ratio
$23.30
★ N/A
Revenue Growth
★ 5.04
N/A
52 Week Low
$41.53
$69.81
52 Week High
$55.71
$148.83

Technical Indicators

Market Signals
Indicator
CNA
ABVX
Relative Strength Index (RSI) 27.67 34.28
Support Level $45.20 $74.79
Resistance Level $49.00 $130.96
Average True Range (ATR) 0.93 4.47
MACD -0.17 -1.17
Stochastic Oscillator 15.36 11.16

Price Performance

Historical Comparison
CNA
ABVX

About CNA CNA Financial Corporation

CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.

Share on Social Networks: